Therapeutics - 122 News for the pharma industry

Tip: You can further refine your news selection by departments, organizations and countries.

Therapeutics - 122 News for the pharma industry

Tip: You can further refine your news selection by departments, organizations and countries.

image description

Side-effect free RNA therapeutics active only in diseased cells

SRTD biotech secures seed financing

18-Nov-2024 - Jülich-based biotech start-up SRTD biotech GmbH has successfully closed a seven-figure seed financing round. The company will use the fresh capital to accelerate the development of novel RNA therapeutics. Based on a proprietary platform technology, SRTD biotech aims to develop highly efficient ...

therapeutics cancer therapeutics RNA therapeutics
image description

ImmunOs Therapeutics raises $11 million and further strengthens investor base

“ImmunOs Therapeutics has a very innovative approach to target myeloid checkpoints which are potentially the next major breakthrough in immuno-oncology”

24-Sep-2024 - ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, announced the closing of a Series C financing round of $11 million. The ...

therapeutics immunotherapeutics autoimmune diseases
image description

Efficiency boost for drug discovery

Insilico Medicine and Inimmune achieved collaboration to revolutionize immunotherapy with AI-driven drug discovery

12-Sep-2024 - Insilico Medicine announced that the company has achieved a groundbreaking collaboration with Inimmune, which will utilize Chemistry42, Insilico's proprietary generative artificial intelligence (AI) technology to accelerate the discovery and development of next-generation ...

therapeutics immunotherapeutics active ingredient research
image description

Biotechnology start-up using AI to translate nature into new medicines

Enveda Biosciences announces $55M in new funding to accelerate platform and advance multiple candidates to clinical trials

19-Jun-2024 - Enveda Biosciences announced a new financing round of $55 million to add to its $119 million combined Series B and B1. New investors Premji Invest, Lingotto Investment Fund, Microsoft, and The Nature Conservancy participated in the round alongside existing investors Kinnevik, True Ventures, FPV, ...

therapeutics oral therapeutics anti-inflammatory drugs
image description

Game changer in fighting cancer: BioCopy expands corporate portfolio with acquisition of start-up Perspix Biotech

"BioCopy is able to accelerate the development time from a decade long marathon to a fast sprint"

11-Apr-2024 - BioCopy AG, a research-based biotechnology company headquartered in Basel, Switzerland, announced the acquisition of Perspix Biotech GmbH. Founded in 2021 and based in Frankfurt am Main, Germany, Perspix Biotech with its end-to-end automated platform roPROTix combines artificial intelligence and ...

therapeutics biotherapeutics artificial intelligence
image description

Tubulis closes upsized €128 million Series B2

"This substantial financing from a syndicate of global specialist biotech investors recognizes Tubulis’ unique position in the ADC space"

18-Mar-2024 - Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round was co-led byEQT Life Sciences and Nextech Invest Ltd, on behalf of one or more funds managed by it, with participation from new US-based funds, Frazier Life ...

therapeutics cancer therapeutics antibody-drug conjugate
image description

Insamo launches with $12m funding to develop best-in-class membrane-permeable macrocyclic peptides

"Turn-key" solution from Insamo to revolutionise drug discovery

26-Feb-2024 - Insamo, a biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides, announced $12 million in seed capital from Playground Global, venBio, and MRL Ventures Fund (MRLV). MRLV is a corporate venture arm of Merck & Co., Inc which invests in ...

therapeutics oral therapeutics artificial intelligence
image description

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

"DISCO is uniquely positioned to transform cancer care"

18-Jan-2024 - DISCO Pharmaceuticals ("DISCO"), a specialist biotech unlocking thesurfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth. The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed financing ...

therapeutics cancer therapeutics antibodies
image description

Oral peptides: A new era in drug development

The research opens the door to a new class of orally available drugs, addressing a long-standing challenge in the pharmaceutical industry

10-Jan-2024 - For decades, a substantial number of proteins, vital for treating various diseases, have remained elusive to oral drug therapy. Traditional small molecules often struggle to bind to proteins with flat surfaces or require specificity for particular protein homologs. Typically, larger biologics ...

therapeutics oral therapeutics biologics
image description

Ethris and Heqet Therapeutics announce Collaboration

Collaboration will harness the potential of non coding RNAs (ncRNAs) in regenerating heart tissue

14-Nov-2023 - Ethris GmbH and Heqet Therapeutics, a biotechnology spin-out company from King’s College London active in the field of regenerative medicine, announced a collaboration agreement to harness the potential of ncRNA for heart tissue regeneration following acute myocardial infarction (heart attack) ...

therapeutics RNA therapeutics heart
Search all

These products might interest you

LPD_GPS_ Centrifugation Project

LPD_GPS_ Centrifugation Project by Thermo Fisher Scientific

Powerful at Every Turn – Meet the NEW General Purpose Centrifuge Family

The most versatile centrifuges designed to fit your application needs

centrifuges
View product
Thermo Scientific™ Heracell™ Vios™ CR CO2 Incubators CTS™ Series

Thermo Scientific™ Heracell™ Vios™ CR CO2 Incubators CTS™ Series by Thermo Fisher Scientific

Next-generation cleanroom confidence for cell therapy research and manufacturing

The first-to-market third party certified cleanroom-compatible CO2 incubator

cell culture incubators
View product
Show all therapeutics
Haven't found the right news yet?

The bionity.com news search

Start your targeted search now with a wide range of filter options. Our database includes an archive of 27,246 life science news from business and science, which you can search by topic and organization, filtered by time and geography.

Start news search now